Chemoprevention of breast cancer.
O'Shaughnessy
J A
JA
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control* / Q000628:therapy; D002278:Carcinoma in Situ / Q000235:genetics / Q000517:prevention & control*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D053138:Cyclohexenes; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D019833:Genistein; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D000077222:Limonene; D008875:Middle Aged; D039821:Monoterpenes; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics / Q000517:prevention & control* / Q000628:therapy; D012176:Retinoids / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use*; D013729:Terpenes / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D053138:Cyclohexenes; D004965:Estrogen Antagonists; D007529:Isoflavones; D039821:Monoterpenes; D012176:Retinoids; D013729:Terpenes; D013629:Tamoxifen; C032208:perillyl alcohol; D003687:Dehydroepiandrosterone; D000077222:Limonene; D019833:Genistein